HMPL-004 (Hutchison Medipharma)

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameHMPL-004 (Hutchison Medipharma)
Drug Alias NameHMPL-004
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionInterleukin-1 beta inhibitorsNuclear factor NF-kappa-B complex inhibitorsTumor necrosis factor α inhibitors
TargetsNuclear factor NF-kappa-B complexTumor necrosis factor αInterleukin-1 beta
Therapy Area/IndicationsColitis, Ulcerative
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesHutchison Medipharma Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesHutchison Medipharma Ltd
Active IndicationsN/A
Inactive IndicationsColitis, Ulcerative

Other Information

ATC CodeN/A
Related LinksN/A